LIRAGLUTIDE | A212552 | FRESENIUS KABI USA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Covington & Burling LLP on behalf of Novo Nordisk Inc. FDA-2024-P-5966 · 4 docket documents Covington & Burling LLP on behalf of Novo Nordisk Inc. filed this citizen petition pursuant to 21 C.F.R. § 10.30 requesting that the FDA publish a notice excluding liraglutide from the 503B Bulks List, rescind the 503B Interim Policy in its entirety, and exclude liraglutide from Category 1 of the 50 | Other | 2025-01-02 | Open | Novo Nordisk Inc. |
Public Citizen Health Research Group - Citizen Petition FDA-2012-P-0404 · 4 docket documents Public Citizen Health Research Group filed this citizen petition in April 2012 pursuant to sections 355(e) of the Federal Food, Drug, and Cosmetic Act and 21 C.F.R. 10.30, requesting that the FDA immediately remove liraglutide (Victoza) from the market because known increased risks of thyroid cancer | Other | 2012-05-02 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.